Meeting
2016 ASCO Annual Meeting
Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.
Authors
Hossein Borghaei
Fox Chase Cancer Center, Philadelphia, PA
Hossein Borghaei , Julie R. Brahmer , Leora Horn , Neal Ready , Martin Steins , Enriqueta Felip , Luis G. Paz-Ares , Oscar Arrieta , Fabrice Barlesi , Scott Joseph Antonia , Jerome Fayette , Naiyer A. Rizvi , Lucio Crino , Martin Reck , Wilfried Ernst Erich Eberhardt , Matthew David Hellmann , Kaushal Desai , Ang Li , Diane I. Healey , David R. Spigel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01642004, NCT01673867
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9025)
DOI
10.1200/JCO.2016.34.15_suppl.9025
Abstract #
9025
Poster Bd #
348
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).
First Author: Jonathan Wade Goldman
Poster
2022 ASCO Annual Meeting
Combi-TED: A multicenter, phase II, open-label, randomized trial evaluating efficacy of OSE2101 plus docetaxel or OSE2101 plus nivolumab as second-line therapy in metastatic NSCLC progressing after first-line chemo-immunotherapy.
First Author: Federico Cappuzzo
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I trial combining plinabulin and nivolumab for metastatic NSCLC: Trial in progress.
First Author: Nicolas Villanueva
Poster
2016 ASCO Annual Meeting
Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials.
First Author: Meena Venkatachalam